Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Endometrial Cancer Recurrent 1Breast Neoplasms 1Advanced Cancers 1Adenocarcinoma of Lung 1ALK or ROS1-positive NSCLC 1

Interventions

Cyclophosphamide 6Isotretinoin 5thymoglobulin 4fludarabine phosphate 4fludarabine 4aldesleukin 4Topotecan 4Temozolomide 4Melphalan 4Irinotecan 4Etoposide 4ribociclib 3Thiotepa 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Busulfan 3Bone Marrow Transplantation 3Antilymphocyte Serum 3temsirolimus 2omburtamab I-131 2dinutuximab 2Vincristine 2Tretinoin 2TPI-287 2Stem Cell Transplantation 2Rituximab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroblastoma × Crizotinib × Clear all
NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated
44 enrolled 22 charts 1 FDA
CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡